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Abstract
The molecular response to hypoxia is a critical cellular process implicated in cancer, and a target for drug development. The
activity of the major player, HIF1a, is regulated at different levels by various factors, including the transcription factor ELK3.
The molecular mechanisms of this intimate connection remain largely unknown. Whilst investigating global ELK3-chromatin
interactions, we uncovered an unexpected connection that involves the microRNA hsa-miR-155-5p, a hypoxia-inducible
oncomir that targets HIF1a. One of the ELK3 chromatin binding sites, detected by Chromatin Immuno-Precipitation
Sequencing (ChIP-seq) of normal Human Umbilical Vein Endothelial Cells (HUVEC), is located at the transcription start site of
the MIR155HG genes that expresses hsa-miR-155-5p. We confirmed that ELK3 binds to this promoter by ChIP and
quantitative polymerase chain reaction (QPCR). We showed that ELK3 and hsa-miR-155-5p form a double-negative
regulatory loop, in that ELK3 depletion induced hsa-miR-155-5p expression and hsa-miR-155-5p expression decreased ELK3
expression at the RNA level through a conserved target sequence in its 39-UTR. We further showed that the activities of hsa-
miR-155-5p and ELK3 are functionally linked. Pathway analysis indicates that both factors are implicated in related
processes, including cancer and angiogenesis. Hsa-miR-155-5p expression and ELK3 depletion have similar effects on
expression of known ELK3 target genes, and on in-vitro angiogenesis and wound closure. Bioinformatic analysis of cancer
RNA-seq data shows that hsa-miR-155-5p and ELK3 expression are significantly anti-correlated, as would be expected from
hsa-miR-155-5p targeting ELK3 RNA. Finally, hypoxia (0% oxygen) down-regulates ELK3 mRNA in a microRNA and hsa-miR-
155-5p dependent manner. These results tie ELK3 into the hypoxia response pathway through an oncogenic microRNA and
into a circuit implicated in the dynamics of the hypoxic response. This crosstalk could be important for the development of
new treatments for a range of pathologies.
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Introduction
Reduction in the availability of oxygen has drastic effects on
cells and tissues [1]. Depending on the organ and the distance
from blood vessels, the concentration of oxygen varies between 2–
9%. Hypoxia occurs with increasing severity below 2% oxygen
until the absence of oxygen and anoxia [2]. A common feature of
tumours is that they are hypoxic, and cancerous cells are specially
adapted to a hypoxic environment [3]. The key regulator of
hypoxia is HIF1a (hypoxia inducible factor 1 alpha). In normoxia,
HIF1a is degraded, whereas in low oxygen conditions HIF1a is
stabilized and translocates to the nucleus, where it interacts with its
binding partner HIF1b to form a transcription factor that can
regulate gene transcription [4]. This stabilization allows for a rapid
response to oxygen deprivation. However, other factors are also
involved in the hypoxia response, including the ETS family
member ELK3 [5,6].
ELK3 is an ETS transcription factor that links MAPK kinase
signalling to transcription. It is a member of a subfamily of
Ternary Complex Factors (TCF) factors whose peculiarity is to
interact with the serum response factor (SRF) [7]. First identified
as a repressor of c-Fos expression [8], it has been shown to have
roles in cell migration through the control of PAI-1 [9],
angiogenesis through VEGF [10] and vascular integrity through
EGR1 [11]. Normally functioning as a repressor of gene
expression by way of two repressor domains [12,13] it can
become an activator after being targeted by MAPK following
activation of the Ras signaling pathway [8]. A role in gene
regulation under hypoxia was first suggested when it was observed
that all previously identified ELK3 target genes were also
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e113050
responsive to hypoxia and it was demonstrated that ELK3 protein
was degraded in low oxygen conditions [5]. Subsequently, its
importance in the hypoxic response was revealed by a micro-array
study, which showed that the majority of the genes that required
HIF1a for their regulation under hypoxia also required ELK3 [6].
ELK3 and HIF1a have been proposed to be involved in distinct
yet intricately linked hypoxia-induced signalling pathways [14], yet
the ways they interact to regulate gene expression is still not fully
understood.
The discovery of a class of microRNAs that respond to hypoxia
[15] demonstrates a new facet not only to the hypoxic response,
but also to novel mechanisms for its regulation with important
implications for disease, including cancer [16,17]. Several cases
have been documented of microRNAs targeting key components
of the hypoxia pathway [18,19,20,21]. HIF1a is normally
regulated at the protein level; however it was shown that a
microRNA, hsa-miR-155-5p, can target the 39UTR of the HIF1a
mRNA message [20]. Furthermore, this was revealed to be a built-
in feedback loop into the hypoxia system, by the discovery of an
HRE at the MIR155HG (BIC) gene promoter, which expresses
the miR, and the revelation that miR-155 expression can be
driven in hypoxia by HIF1a [20]. More recently, hsa-miR-155-5p
has been shown to target pVHL [19], suggesting it is part of a
complex management system for the control of hypoxic response
pathways. Another microRNA component of this pathway is hsa-
miR-210-5p, which is directly regulated by HIF1a [22] and is
often described as the master hypoxamir [23,24]. Interestingly,
ELK3 has been suggested to be a target for both hsa-miR-155-5p
[25,26] and hsa-miR-210-5p [23]. Confirmation of this finding
would cement ELK3 into the hypoxic response and consolidate
the importance of ELK3 in regulation of hypoxia.
In this study, we demonstrate a feedback mechanism involving
hsa-miR-155-5p that can regulate the expression of both ELK3
and HIF1a under hypoxia. Our study integrates ELK3 deeper
into our understanding of the cellular response to oxygen and
underlines its importance in cellular processes and cancer.
Materials and Methods
Cell culture and hypoxic treatment
Mouse skin endothelial (SEND) cells (generous gift from Kari
Alitalo) were grown in minimal essential medium (MEM), 10%
Fetal Calf Serum (FCS) and 40 mg/ml Gentamicin. Human
Umbilical Vein Endothelial Cells (HUVEC; ATCC, Cat.
CRL1730) were grown in Dulbecco’s Modified Eagle Medium/
Hams F-12- Kaighn’s (DMEM/F12K (1:1) supplemented with
100 mg/ml Heparin, 50 mg/ml Endothelial Cell Growth Supple-
ment, 2 mM Glutamine) 10% Fetal Calf Serum (FCS) and 40 mg/
ml Gentamycin. The normoxic conditions were: 20% O2, 5%
CO2 and 37uC in a ThermoForma incubator. The hypoxic
conditions (0% oxygen) were achieved using the Anaerocult A
system (Millipore).
Northern Blotting
SEND cells [27] were incubated in 0% oxygen for the indicated
times, total RNA was extracted, run on 1% agarose-formaldehyde
denaturing gels, transferred to nitrocellulose membranes and
hybridized with full length mouse Elk3 and RPLPO (Ribosomal
Protein, Large, P0) 32[P] labelled probes and exposed to films or
Phosphoimager screens for quantification. Elk3 (band 3) intensities
were corrected for variations in the housekeeping gene RPLPO,
normalised to time 0 h and plotted.
Figure 1. ELK3 DNA binding in HUVEC cells in normoxia. (A)
Diagramatical traces of UCSC Genome Browser (http://genome-euro.
ucsc.edu/) tracks showing ChIP-seq normalized bedgraphs around the
TSS for BAD, EGR1, c-FOS and PAI1. Data is normalised to 107 total tags.
Each representation shows 2Kb of sequence data. Precise locations are:
BAD - chr11:64,051,548-64,053,547, EGR1 - chr5:137,799,444-
137,801,443, FOS - chr14:75,743,992-75,745,991 and PAI1 -
chr7:100,768,727-100,770,726. (B) ChIP and QPCR to validate the ChIP-
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RNAi and miR mimic/inhibitors
HUVEC cells were transfected at 70–80% confluence. For
RNA interference (RNAi), cells were transfected with siRNAs
(final concentration of 25 nM) using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. The siRNA
against ELK3 (59-CAUGGUAGUCUAGAUUUA-39) targets the
39UTR (made to order from Sigma), the control siRNA is non-
targeting (Table S1 in File S1). MicroRNA mimics and
inhibitors for hsa-miR-155-5p, hsa-miR-210 and their controls
(Table S1 in File S1) were transfected in the same manner to a
final concentration of 5 nM and samples collected after 48 h.
Chromatin Immunoprecipitation (ChIP)
The protocol was adapted from the Upstate ChIP Assay Kit
(Cat. 17–295). HUVEC cells (5–606106) were cross-linked in
normal medium containing 1% paraformaldehyde (Electron
Microscopy Sciences) for 10 min at 37uC. Crosslinking was
stopped by the addition of glycine (0.125 M final). Cells were
washed with PBS and recovered in Triton-X100 lysis buffer.
Nuclei were pelleted and resuspended in 500 ml SDS Lysis Buffer.
Samples were sonicated with a Bioruptor (Dianode) to shear DNA
to 250–500 base-pairs (bp). Cell debris was pelleted and the
chromatin recovered. A fraction was removed as input. Chromatin
for immunoprecipitation (IP) was incubated with primary anti-
hElk3 antibody (#2005– generated in-house using a peptide from
the C-terminus - HMPVPIPSLDRAASPVLLSSNSQKS) over-
night at 4uC with rotation. 25 ml of Protein A Magnetic beads
(Millipore) per sample were washed three times with ChIP dilution
Buffer and added to the chromatin. After 6 h incubation at 4uC
beads were washed two times in the following buffers: low salt,
high salt, LiCl and TE. The beads were resuspended in 250 ml
Elution Buffe r and shaken for 30 minutes at room temperature.
The eluate was separated from the beads and crosslinking reversed
by incubation overnight at 65uC with NaCl (200 mM final). Input
samples were reverse cross-linked at this stage also. DNA was
purified using QIA quick PCR purification kit (Qiagen, 28106)
according to the manufacturer’s protocol.
Sequencing of ChIP products and data analysis
ChIP-seq libraries were prepared using Truseq ChIP-Seq
Sample Prep Kit (Illumina, IP-202-1012) following the manufac-
turer’s protocol with some modifications. Briefly, 10 ng of ChIP
enriched DNA or control DNA were end repaired using T4 DNA
polymerase, Klenow DNA polymerase and T4 Poly Nucleotide
Kinase. A single ‘A’ nucleotide was added to the 39 ends of the
blunt DNA fragments with Klenow (39 to 59exo minus). The ends
of the DNA fragments were ligated to double stranded adapters
using T4 DNA ligase. The ligated products were enriched by PCR
(30 sec at 98uC [10 sec at 98uC, 30 sec at 65uC, 30 sec at 72uC] x
14 cycles; 5 min at 72uC), and then size selected and purified using
Agencourt AMPure XP beads (#A63881, Beckman). Prior to
analyses, DNA libraries were checked for quality and quantified
seq. The regions amplified are indicated below the peaks in A. The
negative locus is an intergenic location at Chr12: 96463102–96463229
(build: GRCh37/h19) that would not be expected to bind ELK3, and
indeed there is no peak in the ChIP-seq data (track not shown). (C)
Localisation of ELK3 DNA binding sites as determined by HOMER
(http://homer.salk.edu/homer/index.html) annotation of ELK3 peaks
(MACS cutoff 10–10). (D) Motif analysis by MEME-ChIP (http://meme.
nbcr.net/meme/cgi-bin/meme-chip.cgi). The motif shown was found in
707 of 1000 randomly selected peaks and was centrally distributed.
doi:10.1371/journal.pone.0113050.g001
Table 1. Elk3/hsa-miR-155-5p KEGG pathway correlation.
Pathway Name – Elk3 P-Value Pathway Name – hsa-miR-155-5p P-Value
Pathways in cancer 2.60E-06 Colorectal cancer 2.38E-07
Axon guidance 2.56E-05 Pathways in cancer 1.27E-06
Endocytosis 4.40E-05 HTLV-I infection 3.18E-06
Insulin signaling pathway 9.46E-05 Renal cell carcinoma 4.11E-06
Neurotrophin signaling pathway 1.12E-04 T cell receptor signaling pathway 6.55E-06
Fc gamma R-mediated phagocytosis 2.43E-04 B cell receptor signaling pathway 1.34E-05
Chronic myeloid leukemia 3.49E-04 Neurotrophin signaling pathway 1.53E-05
Cell cycle 6.94E-04 mTOR signaling pathway 1.68E-05
Spliceosome 1.02E-03 Endometrial cancer 5.35E-05
Small cell lung cancer 1.34E-03 MAPK signaling pathway 1.24E-04
Ubiquitin mediated proteolysis 1.47E-03 Hippo signaling pathway 1.76E-04
Mismatch repair 3.76E-03 Osteoclast differentiation 2.28E-04
Oocyte meiosis 4.35E-03 Pancreatic cancer 2.48E-04
MAPK signaling pathway 5.34E-03 Ubiquitin mediated proteolysis 1.23E-03
Prostate cancer 5.54E-03 Prostate cancer 1.52E-03
p53 signaling pathway 6.62E-03 Hepatitis B 2.00E-03
Purine metabolism 8.69E-03 Melanoma 2.27E-03
Adherens junction 9.03E-03 Cell cycle 2.54E-03
Lysosome 1.37E-02 Chronic myeloid leukemia 2.62E-03
Nucleotide excision repair 1.72E-02 Hedgehog signaling pathway 2.75E-03
Bold highlight = similar pathways, hsa-miR-155-5p information obtained from http://starbase.sysu.edu.cn, Elk3 data obtained by submission to DAVID (http://david.abcc.
ncifcrf.gov/home.jsp) of the nearest ENSEMBL gene name to a ChIP-seq peak for the total peak list (MACS-10-05).
doi:10.1371/journal.pone.0113050.t001
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using a 2100 Bioanalyzer (Agilent). The libraries were loaded in
the flow cell at 7pM concentration and clusters were generated
using the Cbot (Illumina, SY-301-2002) and sequenced on the
Illumina Genome Hiseq2500 as single-end 50 base reads following
Illumina’s instructions.
Base calls performed using CASAVA version 1.8.2. ChIP-seq
reads were aligned to the hg19 genome assembly using the Bowtie
aligner (http://bowtie-bio.sourceforge.net/index.shtml, release ,
=1.0.0, with principle parameters: -m 1–strata –best). Peaks were
called using the Model-based Analysis of ChIP-Seq (MACS 1.4.2)
algorithm (http://liulab.dfci.harvard.edu/MACS/). The dataset
density profiles were normalised to 107 tags for visualisation
purposes by Homer (http://homer.salk.edu/homer/ngs/
annotation.html). Peaks were annotated using Homer and
GREAT (http://bejerano.stanford.edu/great/public/html/).
Plasmids
Fragments of the ELK3 59UTR or 39UTR were amplified from
HUVEC genomic DNA using the oligonucleotidess described in
Table S2 in File S1. Corresponding fragments were gel purified
and digested with SpeI (39UTR) or HindIII, NcoI (59UTR) and
inserted into the XbaI site downstream of luciferase (39UTR) or
the HindIII, NcoI site upstream of luciferase (59UTR) of the pGL3
(Promega) vectors as recorded in Table S3 in File S1. Vectors
were verified by sequencing. Mutations to the seed sequences of
the two miR155 sites in the 39UTR were made using PCR
amplification of pGL3 Prom hELK3 39UTR with the oligonucle-
otides detailed in Table S2 in File S1 and Pfu polymerase
(Stratagene). Amplification products were digested with DpnI
(NEB) for 1.5 h at 37uC, purified and transformed. Resulting
plasmids were checked for the correct modification by sequencing.
Multimers of the identified miR-155 target sequences were created
using specific oligonucleotides (Table S2 in File S1) which were
treated with T4 DNA Kinase (NEB) for 30 min 37uC, boiled for
10 min and left to cool. 59 phosphorylated oligonucleotides were
ligated, digested with XbaI and SpeI and cloned into the XbaI site
of the pGL3-Control vector (Table S3 in File S1).
Luciferase Reporter Assays
HUVEC cells were seeded at 80% confluence in 6-well plates
and the next day co-transfected with 100 ng of the appropriate
vectors +500 ng pCMV-Lac Z plasmid as an internal control and
5 nM siRNA (siElk3 39UTR or siRisk) or 20 nM miRNA (mir-
155, miR control or miR-155 inhibiter) using Lipofectamine 2000.
Cell extracts were prepared after 36 h and luciferase activities
were measured with the Promega luciferase assay system
(according to the manufacturer’s protocol) and an EG&G Berthold
luminometer, and corrected for transfection efficiency by using b-
galactosidase activity as an internal control.
Quantitative Real-Time PCR
Total RNA was prepared using TRIREAGENT (Invitrogen)
according to the manufacturer’s instructions. Gene expression was
analysed with one step Quantitative RT-PCR performed on a
Lightcycler 480 system (Roche) using the SYBR Green I kit
(Roche) as per the manufacturer’s instructions. Amplification
specificity was verified by melting curve analysis and the data was
obtained using absolute quantification/2nd Derivative Max with
Lightcycler software. For ChIP, a standard curve was generated
using the input sample and PCR duplicates of the IP were
compared to this curve in order to obtain results relative to input.
For RNA, all samples were tested in a dilution series to ensure that
for every sample the PCR reactions were occurring with optimal
efficiency. Values were obtained by using the dilution series from
one sample to create a standard curve to which the other samples
could be measured against. Normalization was performed using
the internal control RPLPO.
Detection of microRNAs
Total RNA (500 mg) prepared using TRIREAGENT was
treated with polymerase A (NEB, Cat. No. M0276L) for 15 min
at 37uC to add a poly A tail to the ends of the miRNA. Reverse
transcription was then performed using a primer (Table S2 in
File S1) and AMV reverse transcriptase (Roche) according to the
manufacturer’s instructions. Real time QPCR was performed
using a universal primer (Table S2 in File S1) and a primer
specific to the miRNA of interest (Table S2 in File S1) according
Table 2. Elk3/hsa-miR-155-5p PANTHER pathway correlation.
Pathway Name – Elk3 P-Value Pathway Name – hsa-miR-155-5p P-Value
Angiogenesis 4.42E-04 Ras Pathway 4.25E-05
VEGF signaling pathway 1.98E-03 Hedgehog signaling pathway 3.16E-04
PDGF signaling pathway 2.33E-03 Angiogenesis 5.64E-04
Ubiquitin proteasome pathway 8.70E-03 Interleukin signaling pathway 1.62E-03
Axon guidance 3.17E-02 PI3 kinase pathway 1.91E-03
EGF receptor signaling pathway 3.57E-02 Insulin/IGF pathway 3.38E-03
FAS signaling pathway 6.11E-02 TGF-beta signaling pathway 7.33E-03
Huntington disease 7.83E-02 PDGF signaling pathway 9.47E-03
Parkinson disease 7.87E-02 Hypoxia response via HIF activation 1.14E-02
Cytoskeletal regulation by Rho 8.18E-02 – –
Notch signaling pathway 8.41E-02 – –
Endothelin signaling pathway 8.83E-02 – –
Circadian clock system 9.04E-02 – –
Bold highlight = similar pathways, hsa-miR-155-5p information obtained from http://starbase.sysu.edu.cn, Elk3 data obtained by submission to DAVID (http://david.abcc.
ncifcrf.gov/home.jsp) of the nearest ENSEMBL gene name to a ChIP-seq peak for the total peak list (MACS-10-05).
doi:10.1371/journal.pone.0113050.t002
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to the following protocol: 15 min 95uC; 40 cycles of 15 sec 95uC,
30 sec 55uC, 30 sec 70uC; on a Lightcycler 480 system (Roche)
using the SYBR Green I kit (Roche).
MTT Assay
HUVEC cell viability was tested using a MTT assay kit (CT01-
5, Millipore) according to the manufacturer’s instructions. Briefly,
cells were seeded into 8 wells of a 96 well plate at 56103 cells/well.
Each time point used a different plate and 8 wells were completed
with media only. After overnight incubation plates were either
assayed immediately (0 hour time point) or placed in either
normoxic or hypoxic conditions for 24 or 48 hours. MTT solution
was added and after 2 hours, during which the MTT was
metabolised, isopropanol with 0.04N HCL was added to solubilize
the formazan. After 30 minutes incubation the absorbance was
measured at a wavelength of 550 nm.
HUVEC tube formation assays
Transfected HUVEC were seeded at a concentration of 5500
cells in 75 ml of endothelial growth media per well of a 96 well
plate on top of gelled reduced growth factor Basement Membrane
Extract (BD Bioscience, Cat. No. 356237) and incubated for 6 h
at 37uC in 5% CO2. Photographs were taken using an EVOS XL
Core Imaging System for transmitted-light microscope using the x
10 objective. Tube formation was evaluated using Adobe Photo-
shop CS4 Extended-Ruler software (an average of 5 fields were
used).
In-vitro wound-healing (scratch) assays
HUVEC cells were trypsinised 36 h after transfection, counted
and placed in 24 well plates at 100% confluence (200 000 cells/
well). Cells were left overnight to attach and scratched with a
sterile 200 ml pipette tip. Plates were washed twice with PBS to
remove detached cells and incubated in the complete growth
medium. Photographs were taken immediately (0 h) and at 12 and
24 h, using an EVOS XL Core Imaging System for a transmitted-
light microscope equipped with 4x objective and the migration was
evaluated using Adobe Photoshop CS4 Extended-Ruler software
(1000 mm=458 pixels).
Western blots and antibodies
Immunoblotting was performed as described in Serchov et al
[14]. The antibody used and dilutions were as follows: rabbit anti-
human ELK3-2005 (generated in-house using a peptide fragment
from the C-terminus - HMPVPIPSLDRAASPVLLSSNSQKS) 1/
1000, mouse anti-human TBP 1/1500 (clone 3TF1/3G3– Active
Motif), HIF1a 1/1000 (NB100-134, Novus Biologicals). Films
were scanned with a Chemi Genius 2 Bioimaging system and
quantified with Quantity 1 software (BioRad).
Figure 2. ELK3 feedback loop with hsa-miR-155-5p. (A) ELK3
DNA binding to the BIC (MIR155HG) gene promoter as shown in the
ChIP-seq normalised bedgraph and by ChIP-QPCR in comparison to the
negative locus at Chr12: 96463102–96463229 (Three separate experi-
ments, error bars represent the S.D. between experiments). (B) miR-155
expression in cells treated with siRNA against ELK3 (Four transfection
experiments, error bars represent the S.D.). (C) HUVEC cells treated with
miR-155, miR-210 or control miR were analysed for mRNA expression of
ELK3, HIF1a and NDUFA4 by RT-QCPR (Three separate transfection
experiments, error bars represent S.D., **p,0.01, *p,0.05). (D) Protein
expression of ELK3 after treatment with siRNA targeting ELK3, control
siRNA, miR-155 mimic, control miRNA or miR-155 inhibitor as described
in Table S1 in File S1. The loading control was TBP. Quantification of
the films from two independent experiments showed that the levels of
Elk3 that remained were 40% for siElk3 compared to control, 70% for
hsa-miR-155-5p compared to miR Control, and 130% for hsa-miR-155I
compared to miRControl. The p values were 0.007, 0.04 and 0.02,
respectively, using a Student t-test. (E) ChIP using anti-ELK3 antibody on
cells treated with siELK3, miR-155 mimic or control. ELK3 DNA binding
was measured at FOS, EGR1, BAD and the negative locus described in
Figure 1. Percentage DNA binding compared to input was measured by
QPCR (Two separate transfection experiments, error bars represent the
standard deviation).
doi:10.1371/journal.pone.0113050.g002
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Statistical Analysis
All data are average 6 the standard deviation of the average.
Statistics were performed using unpaired Student’s t-Test.
Results
Identification of genome wide ELK3-chromatin
interactions by ChIP-seq
In order to locate ELK3 DNA binding sites on a genome wide
scale, we performed a chromatin immunoprecipitation followed by
deep sequencing (ChIP-seq) experiment. The antibody was
validated by analysing ELK3 binding to the c-FOS promoter (a
previously identified target gene [8]) after transfection with either
siRNA against ELK3 or a ELK3 over-expression vector.
Specificity was shown by decreased binding after treatment with
siRNA and increased binding after over-expression (Figure S1).
Similar results were obtained with two other antibodies against
different epitopes of ELK3 (#2620 and Sigma Prestige
HPA001600, data not shown). ChIP-seq was performed on
HUVEC (human umbilical vein endothelial cells) due to the high
endogenous levels of ELK3 and their relevance for the physiolog-
ical functions of ELK3 in angiogenesis [10,28,29]. The ChIP-seq
revealed nearly 9 000 peaks when the MACS cut-off score was set
to 10–10. Selected ChIP-seq peaks were validated in separate
experiments by ChIP followed by QPCR (Figure 1A–B). We
detected ELK3 DNA binding at the locations identified in the
ChIP-seq, at levels significantly above the negative control. The 9
000 selected peaks were analysed to determine their location
relative to genomic features (HOMER), the presence of centrally
located motifs (MEME) and the functions of the closest associated
genes. The largest proportion (45%) of the peaks was found to be
located between 1000 bp upstream to 100 bp downstream of
transcriptional start sites (Figure 1C). The summits of the peaks
predominantly contain a centrally located CCGGAAG sequence
(Figure 1D), which closely matches the ETS-motif, and in
particular the sequences recognized by the other TCF family
members, ELK1 and ELK4 [30,31,32]. ELK3-DNA binding sites
are preferentially located near genes involved in ‘‘pathways in
cancer’’ (KEGG; Kyoto encyclopedia of genes and genomes) and
‘‘angiogenesis’’ (PANTHER; protein analysis through evolution-
ary relationships) (Tables 1 and 2).
An ELK3/hsa-miR-155-5p regulatory loop
Some of the ELK3-peaks were found to be associated with
genes that produce microRNAs (miRs, Table S4 in File S1).
Since ELK3 regulates gene expression in response to hypoxia [5],
we focused on miRs that are regulated by hypoxia [hypoxamirs;
Table S4 in File S1; [15,16]]. We selected for further study the
Figure 3. Identification of hsa-miR-155-5p target sites on the
ELK3 39-UTR. (A) Homology between hsa-miR-155-5p and two
sequences (S1 & S2) in the human ELK3 gene and conservation in
other genera. The RNA sequence of hsa-miR-155-5p and the non-
coding sequences of the genes are shown, and the boxes indicate
blocks of conservation. The UCSC genome browser was used to locate
the predicted target sequences. (B) Complementarity between hsa-miR-
155-5p and the HIF1a site identified by Bruning et al, [20], S1 & S2 in the
ELK3 39UTR, and the mutants S1 mut and S2 mut. Potential base-pairs
are indicated. (C) Schematic representations of the luciferase reporter
constructs with the locations of the target sites S1 & S2 in the ELK3
39UTR. (D) Luciferase expression of the different constructs
(59UTR=pGL3P-hELK3-5’UTR; 39-UTR=pGL3P-hELK3-3’UTR, 39 UTR S1
mut= pGL3P-hELK3-3’UTR-S1mut; 39-UTR S2 mut = pGL3P-hELK3-3’UTR-
S2mut) after cotransfection with hsa-miR-155-5p mimic (mi), siELK3 (si),
miR155 inhibitor (I) (white bars) or the corresponding control mimics,
siRNAs and inhibitors (co, black bars). The experiment was done 3 times
(**p,0.01, *p,0.05). Error bars represent the standard deviation in one
representative experiment.
doi:10.1371/journal.pone.0113050.g003
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MIR155HG (BIC) gene, which produces a hypoxamir that is
involved in processes similar to ELK3, including cancer and
angiogenesis [Tables 1 and 2; [19,33,34]]. We initially showed
that ELK3 negatively regulates MIR-155HG expression. ELK3
was found to bind to the MIR155HG gene promoter in
independent ChIP experiments (Figure 2A). Furthermore,
down-regulation of ELK3 with a specific siRNA increased hsa-
miR-155-5p expression. (Figure 2B). Interestingly, we predicted
that hsa-miR-155-5p could also regulate ELK3, since bioinfor-
matics analysis using both miRBase Targets (http://www.ebi.ac.
uk/enright-srv/microcosm/htdocs/targets/v5/) and TarBase
(http://www.microrna.gr/tarbase, [35]) identified several poten-
tial target sites (see below). To test this hypothesis, we compared
the ability of hsa-miR-155-5p to down regulate ELK3 mRNA
expression with hsa-miR-210-5p, for which ELK3 is a validated
target in HUVEC [23]. miRNA mimics were transfected into
HUVEC cells and after 48 hours RNA was extracted and the level
of ELK3, HIF1a and NDUFA4 mRNA was measured. As
expected, hsa-miR-155-5p specifically down-regulated HIF1a,
whereas hsa-miR-210-5p specifically down-regulated NDUFA4
[Figure 2C [20,36]]. ELK3 mRNA was down regulated to a
greater extent by hsa-miR-155-5p than hsa-miR-210-5p. We
tested whether ELK3 expression at the protein level was also
decreased by hsa-miR-155-5p. HUVEC cells were transfected
with hsa-miR-155-5p mimic, inhibitor, siRNA against ELK3 or
the corresponding controls, and endogenous ELK3 protein levels
were measured by western blotting. TBP was used as a loading
control. Hsa-miR-155-5p significantly decreased ELK3 protein
levels, whereas the inhibitor increased ELK3 levels to a small
extent (Figure 2D). We also tested whether hsa-miR-155-5p
reduces binding of ELK3 to target gene promoters. Expression of
the hsa-miR-155-5p mimic and siRNA against ELK3 reduced
ELK3 binding to the FOS, EGR1 and BAD gene promoters in
ChIP experiments (Figure 2E). These results show that ELK3
regulates the MIR-155HG (BIC) gene, and that the gene product,
hsa-miR-155-5p, can regulate ELK3 expression, forming a
double-negative feedback loop.
Presence of a functional hsa-miR-155-5p target site in the
39UTR of ELK3 mRNA
Computational analysis identified two potential hsa-miR-155-
5p target sites in the 39UTR of ELK3 (S1 and S2; Figure 3A–B,
the Elk3 gene non-coding strands are shown to facilitate
comparison with hsa-miR-155-5p). We found that the sites are
conserved from humans to chicken (and Xenopus for Site 2),
suggesting that they are functional. In order to test whether they
mediate the effects of hsa-miR-155-5p, reporters were constructed
with the 39UTR downstream of luciferase coding sequences in
pGL3-promoter (Figure 3C and Materials and Methods). Addi-
tional constructs were made in which the seed sequences were
mutated, thereby decreasing complementarity to hsa-miR-155-5p
(Figure 3B). As expected, transfection with a siRNA targeting the
39UTR of ELK3 significantly reduced luciferase expression from
vectors containing the 39UTR, but not the 59UTR or no UTR
(Figure 3D, data not shown). Transfection of the hsa-miR-155-
5p mimic (mi) reduced luciferase expression relative to the control
(co) for the construct containing the 39UTR but not the empty
vector or the 59UTR construct. The effect on the 39UTR
construct was lost when the first hsa-miR-155-5p target site was
mutated but not the second. Transfection with the hsa-miR-155-
5p inhibitor (I) had no significant effect on luciferase expression
from the 39UTR and 59UTR construct and the vector containing
a mutation of the first hsa-miR-155-5p target site S1. There was a
reproducible increase from the S2 mutant, which was not
investigated further. These data suggest that hsa-miR-155-5p
can target the 39UTR of ELK3 and specifically site S1.
To study whether the target sites were sufficient, we created
luciferase reporter vectors containing multimers of the sites
(Figure 4A). Expression of the hsa-miR-155-5p mimic decreased
luciferase expression from constructs containing 4 copies of S1 or
the target sequence of HIF1a, but had no effect when S1 was
mutated or when S2 was present. Significantly, a construct
containing 9 copies of S1 showed increased sensitivity to the
mimic. We also tested whether expression of the Site 1 multimer
from the luciferase construct could affect endogenous ELK3
mRNA. Expression of the multimer blocked the ability of
Figure 4. Activities of multimerised ELK3 target sites. (A)
Schematic representations of the region of pGL3-Control that contains
luciferase coding sequences, the initiation site of the SV40-early
promoter and the site of insertion of 4 or 9 copies of S1, S2, S1 mut
(S1m) or HIF1a target sequences (Bruning et al,) [20]. (B) Effect of miR-
155 mimic expression on luciferase expression from the indicated
reporters, normalised to the control vector. The error bars represent the
S.D. between two separate transfection experiments. (C) Block of miR-
155 inhibition of endogenous ELK3 mRNA by overexpression of ELK3 S1
(site 1 miR-155 target sequence). miR-155 mimic or miR control were
cotransfected with either the empty control vector or pGL3C-9xS1. Two
independent transfection experiments, each analysed twice by qPCR, as
described in the Methods section. **p,0.01, error bars represent S.D.).
doi:10.1371/journal.pone.0113050.g004
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transfected hsa-miR-155-5p mimic to decrease endogenous ELK3
mRNA levels, whereas the empty vector did not have an effect
(Figure 4D). These data suggest that the first hsa-miR-155-5p
target site, S1, is the functional site, although we cannot exclude
that site 2 may also be functional under certain conditions.
Functional significance of ELK3 regulation by hsa-miR-
155-5p
ELK3 and hsa-miR-155-5p are predicted to be involved in
related processes, including pathways in cancer (KEGG pathway)
and angiogenesis (PANTHER pathway; Tables 1 and 2). These
similarities were investigated by comparing their effects on gene
expression, involvement in several cellular processes (tube forma-
tion, wound closure), expression patterns in cancer and response to
hypoxia. We found that down-regulation of ELK3 by siRNA and
expression of hsa-miR-155-5p had similar up-regulatory effects on
expression of known ELK3 target genes [PHD3, HIG2, TXNIP,
DEPP and CCND1, Figure 5A; [6]]. HUVEC cells form tubes
when grown on matrigel, in a process thought to resemble
angiogenesis in vivo. Down-regulation of ELK3 by siRNA and
Figure 5. Similar effects of miR-155 mimic expression and ELK3 RNA down-regulation on gene expression, tube formation and
migration. (A) mRNA levels of ELK3 target genes, measured by RT-QPCR, 24 h after treatment with either siELK3 or miR-155 mimic, normalised to
the corresponding controls (Four separate transfections were analysed for miR-155 and two for siELK3, error bars represent the S.D. between
experiments.). (B) Tube formation of HUVEC cells after expression of miR-155 mimics or siELK3 in comparison to the controls (representative pictures,
the experiment was repeated 5 times, **p,0.001). The bars represent 500 mm. (C) Cell migration post-transfection with miR-155, siELK3, miR-155
inhibitor or the controls at times 0 h, 12 h and 24 h from the scratch. (Measurements are means of 3 fields per wound. Statistical significance was
determined by student t-test, the experiment was repeated 3 times, *p,0.01, **p,0.001, ***p,0.0001 error bars represent S.D). The bars represent
1000 mm.
doi:10.1371/journal.pone.0113050.g005
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overexpression of hsa-miR-155-5p had similar stimulatory effects
on tube length (Figure 5B) and the % of cells involved in cord
formation (data not shown). Wound closure after scratching
confluent HUVEC cell cultures was similarly stimulated by down-
regulation of ELK3 with siRNA and expression of hsa-miR-155-
5p (Figure 5C). Inhibition of endogenous hsa-miR-155-5p with
an inhibitor decreased the rate of wound closure. Overall, these
results show that down-regulation of ELK3 can have similar effects
as increased expression of hsa-miR-155-5p, as might be expected
from direct targeting of ELK3 by this miRNA.
The expression levels of ELK3 and hsa-miR-155-5p should
anti-correlate in conditions where they interact. Using publically
available large datasets [Starbase [25]], we found significant anti-
correlations in breast cancer (BRCA), head and neck squamous
cell carcinoma (HNSCC) and uterine corpus endometrial carci-
noma (UCEC) (Table 3). In UCEC cancer samples compared to
normal, there are lower levels of ELK3 (Figure 6A) and higher
levels of hsa-miR-155-5p (Figure 6B). There is an anti-correla-
tion between ELK3 and hsa-miR-155-5p in cancer (Figure 6C).
These results raise the possibility that interactions between ELK3
and hsa-miR-155-5p may be functionally relevant in these cancers.
Hsa-miR-155-5p is a hypoxamir [19,20], raising the possibility
that it could regulate ELK3 in hypoxia. Although ELK3 mRNA is
stable in 1% oxygen hypoxia for 24 h in SEND endothelial cells
[5,14], we have evidence for specific degradation of ELK3 mRNA
in more extreme conditions (anoxia, 0% oxygen) in these cells
(Figure S2A–B). Therefore, we examined the effects of very low
oxygen in HUVEC. Anoxia induces rapid stabilization of HIF1a
and the up-regulation of its target gene VEGF (Figure S2C–D), a
marked decrease in ELK3 mRNA expression over 48 hours
(Figure 7A) and up regulation of hsa-miR-155-5p and hsa-miR-
210 (Figure 7B). The hypoxia conditions do not cause extensive
cell death, but rather reversible inhibition of proliferation, as
shown by MTT assays of cells exposed to normoxia and hypoxia
for 24 and 48 hours, and recovery for 24 hours in normoxia
following 48 hours in hypoxia (Figure S2E). In order to
determine whether a microRNA was involved in regulation of
ELK3 mRNA in anoxia, we disrupted the microRNA processing
machinery by down-regulating the essential factor Dicer [37].
Dicer knockdown with a specific siRNA (Figure 7C) decreased
the levels of mature hsa-miR-155-5p and hsa-miR-210-5p and
increased ELK3 mRNA after 48 hours of anoxia. In order to
determine whether hsa-miR-155-5p was involved, we blocked
endogenous hsa-miR-155-5p with a specific inhibitor. Inhibition of
hsa-miR-155-5p resulted in increased Elk3 mRNA levels that were
greater in anoxia than in normoxia (Figure 7D). These results
show that there is a miRNA dependent decrease in ELK3 mRNA
in anoxia that involves hsa-miR-155-5p.
Discussion
In this study, we have discovered a new facet to the traditional
hypoxia pathway and one which links ELK3 and HIF1a even
more closely in terms of their regulation under hypoxic conditions.
Furthermore we have identified a novel target for hsa-miR-155-
Figure 6. Comparison of ELK3 and miR-155 expression in
uterine corpus endometrial carcinoma (UCEC). Corresponding
normal samples Expression levels were compared using the TCGA
dataset and algorithms available at http://starbase.sysu.edu.cn. (A)
Decreased levels of ELK3 in cancer (145) compared to normal (18)
samples(fold change= 0.225, student t-test P-Value= 2.80028e-08). (B)
Increased levels of hsa-miR-155-5p in cancer (387) compared to normal
(32) samples (fold change= 4.669, student t-test P-Value= 5.40827e-17).
(C) Anti-correlation between ELK3 and hsa-miR-155-5p levels 1n cancer
(Pearson correlation with r = 0.255, P-Value= 0.001).
doi:10.1371/journal.pone.0113050.g006
MicroRNA Hsa-miR-155-5p Links ELK3 and Hypoxia
PLOS ONE | www.plosone.org 9 November 2014 | Volume 9 | Issue 11 | e113050
5p, an oncomir, which has shown potential for being a prognostic
factor for some cancers [38]. Specifically, we have shown that
ELK3 and hsa-miR-155-5p are part of a feedback loop, which
may be important for a complete understanding of the cellular
response to hypoxia and importantly, comprehension of the
hypoxic tumour microenvironment. This feedback system could
be important in the formation and/or maintenance of the tumour
vasculature and therefore it may lead to better therapies targeting
the vaculature.
We identified two conserved hsa-miR-155-5p target sites in the
39UTR of ELK3, however we were only able to show one of these
as being functional. The reasons for this are unclear, as both
sequences are very similar; only a better understanding of miRNA
targeting will provide an explanation. It is possible that the second
site may be active in a different context, or that additional co-
factors or 3D structures may be required that are not reproduced
in our assays.
ChIP-seq has been performed on the ternary complex factors
[30,31,32,39]. Ours is the first genome-wide analysis of ELK3-
DNA interactions that has been used to uncover new properties of
ELK3. There is interplay between the TCFs at their binding sites
[40], and more comprehensive analysis is required to resolve the
relationship between these factors. The identified DNA binding
motif for ELK3 is similar, but not identical, to those of ELK1 and
ELK4. Whilst the central CCGGAA is conserved between the
three factors, the importance of the individual base pairs and the
surrounding sequences of the motifs are subtly different. It is
known that the different TCF family members can occupy the
same sites, although whether this is due to redundancy between
the factors or if they perform different roles at the same promoters
remains to be determined. Given the high level of redundancy
between the TCF family members, an important caveat is that
some of the sites identified may only be conditional targets of
ELK3. The slight differences in the DNA binding sites of the three
factors could mean that some sites favour one factor over the
other. The functions of the three factors could also differ in the
way they are targeted by miRNAs. Interestingly, only ELK3
mRNA has hsa-miR-155-5p, as determined by database searches
of miRbase Targets and Targetscan. Completing this form of
Table 3. Elk3:hsa-miR-155-5p Pearson correlations in cancer.
Cancer Type Sample Number R p-value
Breast cancer (BRCA) 748 20.12283 0.000761416
Head and neck squamous cell carcinoma (HNSC) 428 20.09944 0.0397535
Uterine corpus endometrial carcinoma (UCEC) 161 20.25464 0.0011152
doi:10.1371/journal.pone.0113050.t003
Figure 7. ELK3 mRNA in HUVEC cells is downregulated in
anoxia by a mechanism that involves hsa-miR-155-5p. (A) ELK3
mRNA expression in HUVEC at 0% oxygen normalised to 0 h in
normoxia (Four separate experiments, error bars represent S.D.). (B)
Induction of hypoxamir hsa-miR210-5p and hsa-miR155-5p expression
in 0% oxygen. Three separate experiments, error bars represent the S.D.
between experiments. miR expression is normalized to normoxia 0 h.
(C) ELK3 mRNA expression under anoxia (0% oxygen) after treatment
with the miR-155 inhibitor (miR-155I, see Table S1 in File S1) relative
to the inhibitor control. Three separate experiments, error bars
represent the S.D.
doi:10.1371/journal.pone.0113050.g007
Figure 8. Model of the anoxia-ELK3-miR155 regulatory circuit.
ELK3 blocks hsa-miR-155-5p expression in normoxia. Under anoxic
conditions, hsa-miR-155-5p expression increases due to HIF1a induc-
tion, which in turn leads to decreased HIF1a and ELK3 mRNA
expression. Increased hsa-miR-155-5p expression and decreased Elk3
expression induce ELK3 target genes, angiogenesis and cell migration.
doi:10.1371/journal.pone.0113050.g008
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analysis for the TCF family will hopefully help to reveal the
interplay between and specificities of these three factors.
Whilst we have described the targeting of ELK3 by hsa-miR-
155-5p, there are many other microRNAs that may be able to
regulate ELK3 expression, and some of these may even be hypoxia
regulated. For example hsa-miR23A was identified by Targetscan
as having the potential to target ELK3, is reported as being
hypoxia regulated [15] and is perhaps directly regulated by ELK3
(Table S4 in File S1). ELK3 has been identified experimentally
as a target of another hypoxamir, hsa-miR-210-5p, although there
was only a small effect on ELK3 mRNA and no changes at the
protein level [23]. We found at most small changes in ELK3
mRNA expression with these miRNAs, which were however not
statistically significant (data not shown). It could be that our
methods are not sensitive enough to accurately detect these
changes. It is also possible that under different conditions the effect
of on ELK3 could be more pronounced, as at-yet little is known
about how microRNAs are selective between all their potential
targets. These unanswered questions leave significant scope for
more in-depth analysis to determine all the potential microRNAs
or hypoxamirs that may regulate ELK3.
Downregulation of Elk3 by siRNA and hsa-miR-155-5p did not
always results in identical effects on the expression of Elk3 target
genes (Figure 5A). There could be a number of explanations for
this, and indeed treatment with siELK3 and miR-155 would not
necessarily be expected to have the same effect. It is known that
hsa-miR-155-5p has many other targets, such as HIF1a, which
could explain some of the differences. Additionally it is possible
that hsa-miR-155-5p may target one of the genes directly. Cyclin
D1 has recently been identified as a target for miR-155 [41].
However, we predicted that the two treatments should be broadly
similar, and indeed that is what we observe.
As reported in Bruning et al [20], HIF1a can both regulate the
expression of hsa-miR-155-5p in hypoxia by binding to an HRE
site in the promoter of the MIR155HG (BIC) gene under hypoxic
conditions and in turn be regulated by hsa-miR-155-5p through a
specific target site in the HIF1a 39UTR. Here we report a related
situation for ELK3 with a specific target sequence for hsa-miR-
155-5p in the 39UTR that mediates ELK3 mRNA down
regulation when hsa-miR-155-5p expression increases. We also
identified a role for ELK3 in regulating the expression of this
microRNA, although conversely to HIF1a, since ELK3 acts as a
repressor of miR expression under normal conditions. We have
previously reported on the similarity in the control of gene
expression between ELK3 and HIF1a with both proteins
controlling the expression of many of the same genes under
hypoxia [6]. Here, we identified another link between the two
factors and suggest a common mechanism for regulation through
hsa-miR-155-5p. These data tie ELK3 ever closer into the HIF1a
regulatory pathway.
Whilst hsa-miR-155-5p is a known hypoxamir, it is known that
other factors can induce its expression. Induction of hsa-miR-155-
5p by TNFa through NFkb in 3T3-L1 preadipocytes results in the
inhibition of adipogenesis [42]. It could be that induction of hsa-
miR-155-5p under different circumstances could also imply a
downstream role for ELK3 in those pathways. The nature of the
ELK3-hsa-miR-155-5p relationship under different conditions
could be as important as the one we have described here under
hypoxia.
Hsa-miR-155-5p has been reported to affect various physiolog-
ical and pathological processes, such as hematopoietic lineage
differentiation, immunity, inflammation, viral infections, cancer,
cardiovascular disease and Down syndrome. Hsa-miR-155-5p can
act as an oncogene, but there are also reports of it having tumour
suppressor functions [for reviews see [43,44,45,46]]. The interac-
tions between hsa-miR-155-5p and ELK3 may be expected to be
relevant in some of these. From the current work and previous
studies, directions to follow would be several types of cancer
(Ovarian, Breast and HNSCC), angiogenesis and possibly
hematopoiesis. In previous studies, we have shown that mice
lacking Elk3 have altered blood cell content when exposed to a
hypoxia mimic [5].
From our results, we are able to suggest a basic model
(Figure 8). Under normoxic conditions, ELK3 represses hsa-
miR-155-5p expression. However, under hypoxia, HIF1a is
stabilized and induces hsa-miR-155-5p expression. In turn, hsa-
miR-155-5p feeds-back to inhibit HIF1a and ELK3 mRNA
expression, and to increase ELK3 target gene expression, and in-
vitro angiogenesis and wound closure. A key difference is that for
HIF1a the effect of the feedback is negative whilst for ELK3 it is
double-negative. Double-negative feedback loops are known to
exhibit bistable behaviour and are important in developmental
transcriptional regulation [47]. Interpreting the action of this
model under different hypoxic conditions will require further
work. This model omits some important subtleties. Firstly, we
know that the degradation of ELK3 requires the oxygen
concentration to be below 1%, whereas the induction of hsa-
miR-155-5p in hypoxia can occur at 1% oxygen. Therefore, there
is a graded response depending on the severity of hypoxia. ELK3
protein has been shown to be transported from the nucleus and
degraded under hypoxia. Presumably degradation of the mRNA
under severe hypoxic conditions has implications for the recovery
time on the return to normal oxygen conditions.
In conclusion we have identified a novel mechanism for
regulation of ELK3 under hypoxic conditions and this mechanism
is shared with the hypoxic response factor HIF1a. We have
already provided evidence that these two proteins have a close
relationship in the regulation of the hypoxic response and here we
have identified another strong link. Furthermore, we have
discovered anti-correlations between hsa-miR-155-5p and ELK3
in some types of cancer, suggesting that this relationship has an
important role in some pathologies, which could potentially be
exploited for the development of therapies.
Supporting Information
File S1 Contains supporting tables. Table S1, siRNA/miR
mimics/inhibitors. Suppliers and catalogue numbers are given.
Table S2, Oligonucleotides. Oligonucleotides were designed using
Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/) or integrated de-
sign technologies realtime PCR tool and subsequently purchased
from Sigma. Table S3, Vectors. The vectors used in this work are
listed in the table, and are either based on a commercially
available backbone or were described previously [1]. Table 4,
Hypoxamirs. Highlighted in blue are hypoxamirs identified by
Kulshreshtha et al [2], and highlighted in red are hypoxamirs
identified by Shen et al. [3].
(DOCX)
Figure S1 Validation of the ELK3 antibody for ChIP-
seq. (A) ChIP on HUVEC cells transfected with siRNA against
ELK3 (siELK3) or overexpression plasmid (pTL2hELK3) and the
corresponding controls (siCont and pTL2). DNA in the immuno-
precipitates were analysed by QPCR with primers for a region in
the c-FOS promoter and a negative control DNA region expected
not to bind ELK3.
(TIF)
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Figure S2 ELK3 mRNA degradation in anoxia (0%
oxygen) in SEND cells. (A) Northern blot of total RNA
extracted from SEND cells cultured in 0% oxygen for the
designated times and probed for ELK3 and RPLPO. The
locations of 18S and 28S ribosomal RNA are indicated. (B)
Northern Blot quantification. The major Elk3 band (3, 1,600
bases) was quantified by scanning suitably exposed autoradio-
grams, correcting for RPLPO, and normalizing to the zero time
point. One representative example of four independent experi-
ments is shown. (C) HIF1a induction under 0% oxygen
conditions. HUVEC cells were incubated in 0% oxygen for the
indicated times and whole cell extracts were analysed by western
blotting with antibodies against HIF1a and TBP as a loading
control. (D) VEGF mRNA induction under 0% oxygen condi-
tions. HUVEC cells were incubated in 0% oxygen for the
indicated times, and extracted RNA was analysed by RT-QPCR
for VEGF and RPLPO RNA levels. VEGF RNA levels were
corrected for the internal control RPLPO, and normalized to the
0 h time point. (E) HUVEC cells viability during hypoxia in a
MTT assay in comparison to media without cells. Measurements
were taken at the start of the experiment (lane 1) and after 24 and
48 hours of normoxia (lanes 2 and 3, respectively) or hypoxia
(lanes 4 and 5, respsctively). A further point was taken after
24 hours of re-oxygenation (lanes 6). Error bars represent the S.D.
within the experiment.
(TIF)
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